Macdonald, William
The University of Western Australia · Fiona Stanley Hospital
4 papers on CoChatORCID 0000-0001-9451-1917
Most cited papers
- Verified
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 1,170
- Verified
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., et al. (2024) · The Lancet Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 230
- Verified
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Emmett, L., Subramaniam, S., Crumbaker, M., Nguyen, A., Joshua, A. M., Weickhardt, A., Lee, S.-T., Ng, S., Francis, R. J., Goh, J. C., et al. (2024) · The Lancet Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 195
- Verified
Improving Access to Safe Anesthetic Care in Rural and Remote Communities in Affluent Countries
Orser, B. A., Wilson, C. R., Rotstein, A. J., Iglesias, S. J., Spain, B. T., Ranganathan, P., MacDonald, W. A., Ng, V., O’Leary, S., & Lafontaine, A. (2019) · Anesthesia & Analgesia
Global Health and SurgeryGlobal Health Workforce Issues
Cited by 44
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free